7.275

1.12% -0.075

Biocryst Pharmaceuticals Inc (BCRX)

Overview News Price History Option Chain Financials Why BCRX Down? Discussions Forecast

Biocryst Pharmaceuticals Inc stock is traded at $7.275, with a volume of 1.57M. It is down -1.12% in the last 24 hours and down -4.12% over the past month. BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Previous Close:

$7.35

Open:

$7.38

24h Volume:

1.57M

Relative Volume:

0.79

Market Cap:

$1.50B

Revenue:

$331.41M

Net Income/Loss:

$-226.54M

P/E Ratio:

-5.82

EPS:

-1.25

Net Cash Flow:

$-97.31M

1W Performance:

-10.50%

1M Performance:

-4.12%

6M Performance:

+63.31%

1Y Performance:

+20.32%

1-Day Range:

$7.055

$7.4392

1-Week Range:

$6.845

$8.44

52-Week Range:

$4.03

$8.88

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name

Biocryst Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

919-859-1302

Address

4505 EMPEROR BOULEVARD, DURHAM, NC

Employee

531

Twitter

@biocrystpharma

Next Earnings Date

2024-11-04

Latest SEC Filings

BCRX's Discussions on Twitter

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-18-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Aug-04-23	Upgrade	Jefferies	Hold → Buy
Jul-13-23	Upgrade	BofA Securities	Neutral → Buy
Feb-22-23	Upgrade	Needham	Hold → Buy
Nov-02-22	Upgrade	Evercore ISI	In-line → Outperform
Aug-05-22	Downgrade	Evercore ISI	Outperform → In-line
Aug-05-22	Downgrade	Oppenheimer	Outperform → Perform
Apr-18-22	Downgrade	Barclays	Overweight → Equal Weight
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Dec-10-21	Initiated	Oppenheimer	Outperform
Aug-06-21	Downgrade	Jefferies	Buy → Hold
Aug-03-21	Initiated	Cantor Fitzgerald	Overweight
Mar-01-21	Initiated	Cowen	Outperform
Sep-29-20	Resumed	JP Morgan	Overweight
Jun-17-20	Initiated	BTIG Research	Neutral
May-05-20	Upgrade	Barclays	Equal Weight → Overweight
Nov-15-19	Upgrade	BofA/Merrill	Neutral → Buy
May-24-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-16-18	Resumed	Piper Jaffray	Overweight
Aug-08-18	Resumed	JP Morgan	Overweight
Jul-17-18	Upgrade	BofA/Merrill	Underperform → Neutral
Jun-22-18	Initiated	Seaport Global Securities	Neutral
Jan-02-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Dec-20-17	Initiated	Barclays	Equal Weight
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Sep-06-17	Upgrade	JP Morgan	Neutral → Overweight
Sep-06-17	Upgrade	Jefferies	Hold → Buy
Feb-16-17	Initiated	Ladenburg Thalmann	Buy
Aug-12-16	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-04-16	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-09-16	Reiterated	FBR Capital	Outperform
Feb-09-16	Downgrade	JP Morgan	Overweight → Neutral
Feb-09-16	Downgrade	Needham	Buy → Hold

View All

Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News

01:05 AM

BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Earnings Results, Meets Estimates - MarketBeat

01:05 AM

10:55 AM

BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

10:55 AM

10:18 AM

Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat

10:18 AM

07:29 AM

BioCryst Announces Strong Q3 2024 Revenue Growth - Yahoo Finance

07:29 AM

07:02 AM

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

07:02 AM

05:14 AM

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

05:14 AM

02:29 AM